Author(s): Parienti JJ, Massari V, Rey D, Poubeau P, Verdon R SIROCCO study
Abstract Share this page
Abstract Many antiretroviral therapies, including efavirenz, are associated with increased serum concentrations of low-density lipoprotein cholesterol. In a small 52-week randomized study, we found that switching from efavirenz to nevirapine was associated with significantly decreased low-density lipoprotein cholesterol levels, compared with continuation of efavirenz therapy (P<.04). A switch to nevirapine was associated with no severe adverse events.
This article was published in Clin Infect Dis
and referenced in Journal of Antivirals & Antiretrovirals